Proportion of uterus

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

The proportion of angina-free patients was slightly greater with CABG than with DES-PCI at 6 months (83.7% vs 78.1%) and 12 months (83.5% vs 79.5%), with statistically significant differences at 6 and

Effect: improvement; 83.7% vs 78.1% at 6 months; 83.5% vs 79.5% at 12 months

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%

Among 1,378 HIV-infected women enrolled during pregnancy, 38.3% met ART eligibility criteria (CD4 <200 or <350 with WHO stage III) during pregnancy, and this group had 23.7% mortality by 24 months in

Effect: improvement; 38.3%